Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1236 results
March 2019
-
Ad-hoc Releases
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients… -
Ad-hoc Releases
Novartis plans for Alcon spin-off on April 9, 2019
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange… -
Press Release
Alcon Announces Acquisition of PowerVision, Inc.
Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire… -
Press Release
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019… -
Ad-hoc Releases
Novartis announces change in Sandoz leadership
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced… -
Press Release
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and… -
Press Release
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16… -
Press Release
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…
February 2019
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 22nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of… -
Press Release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut
Die Aktionäre bewilligen die 22. Dividendenerhöhung in Folge. Für 2018 wird die Dividende auf CHF 2.85 (+2%) je Aktie erhöht, was einer Rendite von 3,1% und einem Anteil von etwa 57% des freien… -
Press Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale
Les actionnaires approuvent la 22e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une… -
Ad-hoc Releases
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of…